- Home
- CURR vs ADAG Comparison
CURR vs ADAG Comparison
Compare CURR & ADAG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CURR
- ADAG
- Stock Information
- Founded
- CURR 2013
- ADAG 2011
- Country
- CURR Singapore
- ADAG China
- Employees
- CURR 244
- ADAG N/A
- Industry
- CURR Business Services
- ADAG Biotechnology: Pharmaceutical Preparations
- Sector
- CURR Consumer Discretionary
- ADAG Health Care
- Exchange
- CURR Nasdaq
- ADAG Nasdaq
- Market Cap
- CURR 74.0M
- ADAG 81.9M
- IPO Year
- CURR N/A
- ADAG 2021
- Fundamental
- Price
- CURR $1.54
- ADAG $1.53
- Analyst Decision
- CURR Strong Buy
- ADAG Strong Buy
- Analyst Count
- CURR 1
- ADAG 1
- Target Price
- CURR $3.50
- ADAG $8.00
- AVG Volume (30 Days)
- CURR 101.0K
- ADAG 40.8K
- Earning Date
- CURR 04-16-2025
- ADAG 03-24-2025
- Dividend Yield
- CURR N/A
- ADAG N/A
- EPS Growth
- CURR N/A
- ADAG N/A
- EPS
- CURR N/A
- ADAG N/A
- Revenue
- CURR $46,435,412.00
- ADAG $103,204.00
- Revenue This Year
- CURR N/A
- ADAG $6,488.89
- Revenue Next Year
- CURR N/A
- ADAG $57.50
- P/E Ratio
- CURR N/A
- ADAG N/A
- Revenue Growth
- CURR N/A
- ADAG N/A
- 52 Week Low
- CURR $1.19
- ADAG $1.33
- 52 Week High
- CURR $7.08
- ADAG $3.58
- Technical
- Relative Strength Index (RSI)
- CURR N/A
- ADAG 42.87
- Support Level
- CURR N/A
- ADAG $1.47
- Resistance Level
- CURR N/A
- ADAG $1.92
- Average True Range (ATR)
- CURR 0.00
- ADAG 0.18
- MACD
- CURR 0.00
- ADAG 0.01
- Stochastic Oscillator
- CURR 0.00
- ADAG 34.45
About CURR Currenc Group Inc. Ordinary Shares
Currenc Group Inc is a fintech banking platform for e-wallets, financial institutions and merchants world-wide, delivering frictionless interoperable real-time fund transfers and instant messaging.
About ADAG Adagene Inc.
Adagene Inc platform-driven, clinical-stage biopharmaceutical company engaged in transforming the discovery and development of novel antibody-based cancer immunotherapies. It is principally engaged in research, development and production of monoclonal antibody drugs for cancers. The company's platform is designed to generate therapeutic antibody candidates with functional epitopes and species cross-reactivity as highlighted by the company's immunotherapy pipeline.